172 related articles for article (PubMed ID: 19602998)
1. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.
Dhar D; Spencer JF; Toth K; Wold WS
Mol Ther; 2009 Oct; 17(10):1724-32. PubMed ID: 19602998
[TBL] [Abstract][Full Text] [Related]
2. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
Dhar D; Spencer JF; Toth K; Wold WS
J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
[TBL] [Abstract][Full Text] [Related]
3. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
Dhar D; Toth K; Wold WS
Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
[TBL] [Abstract][Full Text] [Related]
4. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
[TBL] [Abstract][Full Text] [Related]
5. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
[TBL] [Abstract][Full Text] [Related]
6. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
7. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
Spencer JF; Sagartz JE; Wold WS; Toth K
Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
[TBL] [Abstract][Full Text] [Related]
8. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.
Young BA; Spencer JF; Ying B; Tollefson AE; Toth K; Wold WS
Cancer Gene Ther; 2013 Sep; 20(9):521-30. PubMed ID: 23928731
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
[TBL] [Abstract][Full Text] [Related]
10. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
11. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
[TBL] [Abstract][Full Text] [Related]
13. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.
Young BA; Spencer JF; Ying B; Toth K; Wold WS
Cancer Gene Ther; 2013 Sep; 20(9):531-7. PubMed ID: 23928730
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
15. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
17. A fully replication-competent adenovirus vector with enhanced oncolytic properties.
Toth K; Kuppuswamy M; Shashkova EV; Spencer JF; Wold WS
Cancer Gene Ther; 2010 Nov; 17(11):761-70. PubMed ID: 20596091
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
Varnavski AN; Calcedo R; Bove M; Gao G; Wilson JM
Gene Ther; 2005 Mar; 12(5):427-36. PubMed ID: 15647774
[TBL] [Abstract][Full Text] [Related]
19. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
[TBL] [Abstract][Full Text] [Related]
20. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]